Nevro announces publication of data from SENZA Painful Diabetic Neuropathy trial

Nevro announced the publication of 24-month data from the SENZA Painful Diabetic Neuropathy, or PDN, Randomized Controlled Trial, or RCT, the largest RCT to evaluate spinal cord stimulation, or SCS, to treat PDN, in Diabetes Research and Clinical Practice. Globally, the number of people with diabetes has quadrupled in the last two decades, and PDN is one of its most common complications, affecting up to 25% of all people with diabetes. PDN symptoms can have a significant impact on quality of life. These symptoms include numbness, tingling/paresthesia, loss of protective sensation, impaired balance, and reduced response to sensory stimuli. Patients typically manage this complication with oral pain medications, but the efficacy of these medications is relatively low and can result in intolerable side effects for patients. As a result, people with PDN suffer significantly-reduced health-related quality of life, or HRQoL, impaired functionality, and other comorbidities like sleep disorders, depression, and anxiety. Published 24-month data from the SENZA-PDN RCT evaluated the long-term efficacy of high-frequency 10 kHz SCS to treat refractory PDN. The data show that patients who received a high-frequency 10 kHz SCS implant and conventional medical management, or CMM, compared to CMM alone, experienced durable pain relief and significant improvements in both HRQoL and sleep at 24 months post-implantation.